Expression of glucose transporter 1 in triple-negative breast cancer and its relationship with the clinicopathological charac-teristics and prognosis
Objective To analyze the expression level of glucose transporter 1(GLUT-1)in triple-negative breast cancer(TNBC)and explore its relationship with the clinicopathological characteristics and prognosis of patients.Methods Seventy-nine patients with TNBC(TNBC group)who underwent radical surgery in the First Hospital of Jiaxing from January 2019 to January 2021 were selected,and another 40 patients with benign breast diseases(including mastitis,mammary fibroma,etc.)admitted during the same period were enrolled as the control group.Tumor tissues and adjacent tissues of TNBC group and breast biopsy tissues of the control group were collected.The qRT-PCR method was used to detect the expression of GLUT-1 mRNA in tissue specimens.The clinical and pathological data of patients in the TNBC group were collected and followed up every 3 months after surgery until December 2023.Death,tumor recurrence and progression,severe complications(cachexia)and so on at one year of follow-up were defined as poor prognosis.The expression levels of GLUT-1 mRNA in tumor and adjacent tissues of TNBC group and breast biopsy tissues of the control group were compared,so were the expression levels of GLUT-1 mRNA in tumor tissues of patients in TNBC group with different clinicopathological characteristics to analyze the performance of different clinicopathological characteristics in predicting poor prognosis of TNBC patients one year after surgery,the risk factors for death of TNBC patients,and the survival of TNBC patients with different GLUT-1 mRNA expression levels.Results The expression level of GLUT-1 mRNA in the tumor tissue of the TNBC group was higher than that in the adjacent tissue and that of the breast biopsy tissue of the control group(both P＜0.05).However,there was no difference in the expression level of GLUT-1 mRNA between the adjacent tissue of TNBC group and the breast biopsy tissue of the control group(P＞0.05).GLUT-1 mRNA expression level in tumor tissue of TNBC patients with poor differentiation,tumor diameter ≥5 cm,Ki-67 index ≥70％,neurovascular invasion,lymph node metastasis,distant metastasis,and TNM stages Ⅲ to Ⅳ were respectively higher than that of patients with moderate to high differentiation,tumor diameter＜5 cm,Ki-67 index＜70％,no neurovascular invasion,no lymph node metastasis,no distant metastasis and TNM stages Ⅰ-Ⅱ(all P＜0.05).The sensitivity,specificity,and AUC of GLUT-1 mRNA expression level in tumor tissue for predicting poor prognosis of TNBC patients one year after surgery were 0.845,0.812,and 0.842 respectively,with an optimal cutoff value of 0.83,showing high predictive efficacy(P＜0.05).Multivariate Cox regression analysis showed that GLUT-1 mRNA expression level ≥0.83 was an independent risk factor for death in TNBC patients(P＜0.05).The survival time of TNBC patients with GLUT-1 mRNA expression level in tumor tissue ≥0.83 was lower than that of patients with＜0.83 of GLUT-1 mRNA expression(27.9±4.6 months vs.36.5±5.8 months,P＜0.05).Conclusion The expression of GLUT-1 in tumor tissues of TNBC patients is up-regulated,which is closely related to clinicopathological characteristics and prognosis,and may be used as a marker for assessing TNBC patient condition and prognosis.
Triple-negative breast carcinomaGlucose transporter 1Clinicopathological characteristicsPrognosisClinical value
万方数据
维普
